-
EU drug regulator says AstraZeneca shot benefit outweighs risk
*EU DRUG REGULATOR SAYS ASTRAZENECA SHOT BENEFIT OUTWEIGHS RISK
— zerohedge (@zerohedge) April 7, 2021
-
— PiQ (@PriapusIQ) April 7, 2021AstraZeneca's covid-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
Says in reaching conclusion, committee took into consideration all currently available evidence, including the advice from an ad hoc expert group
-
— PiQ (@PriapusIQ) April 7, 2021PRAC noted that blood clots occurred in veins in brain and the abdomen (splanchnic vein thrombosis) and in arteries
EMA confirms overall benefit-risk for AstraZeneca's covid-19 vaccine remains positive
-
— PiQ (@PriapusIQ) April 7, 2021EMA - most of blood clot cases reported related to AstraZeneca's vaccine have occurred in women under 60 years of age within 2 weeks of vaccination
-
— PiQ (@PriapusIQ) April 7, 2021EU health ministers told EMA incoming announcement on AstraZeneca vaccine safety expected to have immediate impact on vaccination plans, vaccine confidence - EU document https://t.co/Pxj9jF06Q6